PZ0356
PF-06291874
≥98% (HPLC)
别名:
N-[4-[(1S)-1-[3,5-Dimethyl-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy]butyl]benzoyl]--alanine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H28F3N3O4
化学文摘社编号:
分子量:
503.51
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
SMILES string
FC(F)(F)c1c[n](nc1)c2c(cc(cc2C)O[C@@H](CCC)c3ccc(cc3)C(=O)NCCC(=O)O)C
InChI key
IBDYYOQKQCCSDP-QFIPXVFZSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
room temp
Quality Level
Biochem/physiol Actions
PF-06291874 is an orally active, potent and selective glucagon receptor antagonist. PF-06291874 exhibits a robust glucose reductions in subjects with type 2 diabetes mellitus.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Esther C Y Lee et al.
Bioorganic & medicinal chemistry letters, 24(3), 839-844 (2014-01-15)
Identification of orally active, small molecule antagonists of the glucagon receptor represents a novel treatment paradigm for the management of type 2 diabetes mellitus. The present work discloses novel glucagon receptor antagonists, identified via conformational constraint of current existing literature
Arthur Bergman et al.
Diabetes research and clinical practice, 126, 95-104 (2017-02-27)
The glucagon receptor antagonist PF-06291874 has demonstrated robust glucose reductions in subjects with type 2 diabetes mellitus (T2DM) on background metformin. This study assessed the pharmacokinetics, pharmacodynamics, safety, and tolerability of PF-06291874 administered as monotherapy in subjects with T2DM. After
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持